119 related articles for article (PubMed ID: 38886836)
1. Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.
Mazard T; Mollevi C; Loyer EM; Léger J; Chautard R; Bouché O; Borg C; Armand-Dujardin P; Bleuzen A; Assenat E; Lecomte T
Cancer Imaging; 2024 Jun; 24(1):77. PubMed ID: 38886836
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
3. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
[TBL] [Abstract][Full Text] [Related]
4. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
[TBL] [Abstract][Full Text] [Related]
5. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
6. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
[TBL] [Abstract][Full Text] [Related]
7. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
8. Extracellular volume fraction can predict the treatment response and survival outcome of colorectal cancer liver metastases.
Li S; Yang X; Lu T; Yuan L; Zhang Y; Zhao J; Deng J; Xue C; Sun Q; Liu X; Zhang W; Zhou J
Eur J Radiol; 2024 Jun; 175():111444. PubMed ID: 38531223
[TBL] [Abstract][Full Text] [Related]
9. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
10. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
[TBL] [Abstract][Full Text] [Related]
11. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
[No Abstract] [Full Text] [Related]
13. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
16. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
[TBL] [Abstract][Full Text] [Related]
17. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
19. Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.
Tranquart F; Dujardin PA; Bouché O; Marcus C; Borg C; Manzoni P; Douillard JY; Labbe-Devilliers C; Terrebonne E; Smith D; Trillaud H; Capitain O; Aubé C; Spano JP; Lucidarme O; Ferru A; Tasu JP; Manfredi S; Bleuzen A; Léger J; Lecomte T
Ultraschall Med; 2018 Oct; 39(5):544-558. PubMed ID: 29232725
[TBL] [Abstract][Full Text] [Related]
20. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
Nagaoka T; Osumi H; Ueno T; Ooki A; Wakatsuki T; Nakayama I; Ogura M; Takahari D; Chin K; Matsueda K; Yamaguchi K; Shinozaki E
Int J Clin Oncol; 2023 Sep; 28(9):1191-1199. PubMed ID: 37349660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]